The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days

Biosimilar medicines are available in therapy areas which represent 65% of the biologics market by value

In Europe, biosimilar medicines have captured 7% more of the biologics market over a 5-year period

Growing number of biologic therapies offers future opportunities for biosimilar development

Medicine Shortages Webinar: Damian Holly Supply Chain Resilience Overview.

White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy

(more…)

Educational material on biosimilar medicines, developed by IGBA (International Generic and Biosimilar Medicines Association)

(more…)

(more…)

Second wave pandemic preparedness: procurement principles

Policy Roadmap for Medicines Manufacturing Leadership

Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns

Medicines For Europe